Evidence map›Paper›PMID 40395914›Full record

ReviewJuntendo medical journal2025

Contribution of Genetics to Parkinson's Disease and Future Prospects.

Manabu Funayama

Abstract readReview
In one paragraph

Review in Juntendo medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. medRxiv : the preprint server for health sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Manabu Funayama

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a systemic neurodegenerative disorder that is characterized by motor and non-motor symptoms. Although aging is the primary risk factor, environmental and genetic factors also contribute to risk, and identifying genetic risks may aid in preventive strategies. The present perspective outlines the two main genetic research strategies: research into familial PD using known causative gene screening and next-generation sequencing, and the analysis of sporadic PD using genome-wide association studies (GWAS). Recent advances in next-generation sequencing have improved gene screening, allowing researchers to quickly and inexpensively identify novel rare variants. However, challenges remain, such as accurately analyzing repetitive sequences and structural variants. The role of neurologists in gathering clinical and genomic data ─ especially from familial cases ─ is crucial. International collaborations, such as the Global Parkinson's Genetic Program, address issues such as population diversity and missing heritability in GWAS. Contributions from Juntendo University include the discovery of PD-related genes and the implementation of validation studies in Japanese populations. We also aim to develop molecular targeted therapies using induced pluripotent stem cells. To elucidate the unknown causes of PD and advance treatment approaches, it is important to continuously conduct genetic research.

Indexed as

geneticsmutationParkinson’s diseaserisk

Identifiers

PMID40395914
PMCPMC12086457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.